Category

• Pipeline2

Organizations

• Bausch + Lomb64
• Alcon, Inc.43
• Eyes On Eyecare43
• American Optometric Association34
• Harrow28
• Glaukos26
• Regeneron22
• Topcon Healthcare22
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• Clinical Trials2
• Dry Eye2
• Dry Eye Disease2
• Eye Drops1

• Organizations: HanAll Biopharma✕

Clear all

Pipeline

HanAll Biopharma kicks off phase 3 DED trial on topical anti-inflammatory

VELOS-4 trial is evaluating tanfanerept for improvement in Schirmer test following last year’s phase 3 primary endpoint miss.

Pipeline

Tanfanercept fails DED phase 3 trial primary endpoints

HanAll Biopharma reports highly statistically significant improvement in secondary measures of VELOS-3 study.